Combretastatin A4

For research use only.

Catalog No.S7783

2 publications

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 M2DHeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXjDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDTT21GVC13IH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;Mz6wNGUuODhizszN MX6xPFc2OzVy
A-549 NULaOIJpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MU\DfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDBMVU1QSCudX7nJINiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NFjlUFcyQDd3M{Ww
MCF-7 MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPFR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= NI[2NYMyQDd3M{Ww
HT-29 NFz2V3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFe0c2VEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NHPEO4EyQDd3M{Ww
MLM melanoma cell M1v0Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2jVWWN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= NUi4d|RqOTh5NUO1NC=>
M14 NFnXTYxEgXSxdH;4bYNqfHliYYPzZZk> M{[0[GlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB4[XNidHXzeIVlKGGpYXnud5QhcHWvYX6gcYVt[W6xbXGgZ4Fv[2W{IDjNNVQqKGOnbHygcIlv\SxiR1m1NF0xNjByMEGg{txO MUGxNlczQTZ2MB?=
SK-OV3 M3n5eWN6fG:2b4jpZ4l1gSCjc4PhfS=> MlrTTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJRme3SnZDDh[4FqdnO2IHj1cYFvKG:4YYLpZY4h[2GwY3XyJEhUUy2RVkOpJINmdGxibHnu[UwhT0l3ME2wMlAxODFizszN Ml;wNVI4Ojl4NEC=
HL60 cells NIXLTFREgXSxdH;4bYNqfHliYYPzZZk> M3K4e|czKGh? MmrGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= NFjIcJAzODd|MUO1OS=>
SK-OV-3 NWDrW2I2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2W0ZlQ5KGh? NUDw[IJ4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxOTNizszN M4D6NlE5PzJ{MUK3
HepG2 cells MUPDfZRwfG:6aXPpeJkh[XO|YYm= M3;0dWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCLQ{WwQVAvODByMUSg{txO M4nQWVE4OTJ5ME[x
ZR-75-1 NEXNZZVEgXSxdH;4bYNqfHliYYPzZZk> MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> NYC5bWN{OTd{NEm2OFk>
HeLa cell MXXDfZRwfG:6aXPpeJkh[XO|YYm= M3PHXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= NULKOopZOTd{NEm2OFk>
HCT116 cell NHz5botEgXSxdH;4bYNqfHliYYPzZZk> M4fBS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiFVEGxOkBk\WyuIHzpcoUtKEmFNUC9NE4xODB|NTFOwG0> NUe2SIljOTd{NEm2OFk>
KBV1 cells M3X0c2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2\ze|czKGh? MnL6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO Mk\1NlA4OzF|NUW=
SKOV3 NYnXb4tPS3m2b4TvfIlkcXS7IHHzd4F6 MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? MojXNlQxOTZyMEK=
SKOV3 cells NWPBeGtWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN MXSyN|c4OjNyOR?=
HeLa cells M3TZRWN6fG:2b4jpZ4l1gSCjc4PhfS=> MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEWxJO69VQ>? NGTlbWEyQTh5OUe1PC=>
DU145 cells NXLNUGFKS3m2b4TvfIlkcXS7IHHzd4F6 NHu2c3REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA2PCEQvF2= NVXSRmpHOjRyMU[wNFI>
DU145 cells MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXe2ZmpsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMEW0JO69VQ>? M3vsTFI{Pzd{M{C5
SK-N-BE NXnKWG9NWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUTqeZFyPzJiaB?= MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTT{1PNUKHIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODB3ODFOwG0> MnnLNlI{Ojl3NkG=
NCIH460 cells NV7mSYhVS3m2b4TvfIlkcXS7IHHzd4F6 M1ztc|Q5KGh? MkDCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNjFOwG0> M4H4TVE5OzB|OES5
KB-VIN10 cells NIjZRVNRem:uaX\ldoF1cW:wIHHzd4F6 M1vWU|czKGh? M{jxS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscJMhd3[ncj3lfJBz\XO|aX7nJHAu\3BiMUewM21FWjFiYX\0[ZIhPzJiaILzJIJ6KG2ndHj5cIVv\SCkbIXlJIF{e2G7LDDJR|UxRTBwMECwO{DPxE1? MWiyNVY1OTdyMB?=
HCT116 cells MYDDfZRwfG:6aXPpeJkh[XO|YYm= NFv2Znc4OiCq MlnrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBcO0ifdHj5cYllcW6nIHnuZ49zeG:{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yMEC3OEDPxE1? M{f1fFIyQTV3NEW0
DU145 cells M4K4[WN6fG:2b4jpZ4l1gSCjc4PhfS=> M33YVFQ5KGh? M1fMUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB6IN88US=> MXuxPFMxOzh2OR?=
RS4:11 cells NV3yUI14WHKxbHnm[ZJifGmxbjDhd5NigQ>? NHjvPZU4OiCq M1rR[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> MV2yOVc5PTZyNR?=
HCT 116 MnrXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MlvMNVE4OTR4MUO=
HeLa cells NGjJfWxEgXSxdH;4bYNqfHliYYPzZZk> NUTpNZR6PzJiaB?= NHzER|VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBz\XOjeoXybY4h[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyPUCuNFAxQSEQvF2= NXLSVJM4OjR4Nkm4PFg>
BNL 1ME A.7R.1 cells NGLkXmJEgXSxdH;4bYNqfHliYYPzZZk> NFnabY1EgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDVkxiMV3FJGEvP1JwMTDj[YxteyxiSVO1NF0xNjByMEmg{txO NWThOGNEOjV5OEW2NFU>
Calu6 NEjSU4NRem:uaX\ldoF1cW:wIHHzd4F6 M17QSVQ5KGh? M{DIfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HseVYh[W[2ZYKgOFghcHK|IHL5JJNx\WO2cn;wbI91d22ndIL5MEBKSzVyPUCuNFAxQTRizszN M{TFeFIyPzd2NEm5
melanoma B16 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHZR49v[2WwdILheIlwdiC5aHnjbEBxem:mdXPld{A2OCViaX7obYJqfGmxbjDv[kBoem:5dHigc4YhdXW{aX7lJI1mdGGwb33hJGIyPiClZXzsJIxqdmVuIFnDOVA:OC5yMEGg{txO MVixNVcyPDZzMx?=
DU145 cells MnLmR5l1d3SxeHnjbZR6KGG|c3H5 NHf4O2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP NWjIfHY4OjB2OU[5NlM>
HCT116 cells NYPvXoFUWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1m0d|czKGh? M136VmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MUGyNVEyOjF|MB?=
HCT15 cells NGHyeYFRem:uaX\ldoF1cW:wIHHzd4F6 NVX1cHdEPzJiaB?= M3TId2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? Moi4NlEyOTJzM{C=
HL60 cells M1T1enBzd2yrZnXyZZRqd25iYYPzZZk> MYO3NkBp NEHsZ2dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NFvvZVUzOTZ4M{OxPS=>
A10 cells NGDZb2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHPw[Wg1QCCq NGPJfXlIem:5dHigbY5pcWKrdHnvckBw\iC{YYSgRVExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NGOzeVAzOjB2NEG2OC=>
HUVEC cells MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoGxOFghcA>? NU\6SXB3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiSGXWSWMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NIrvN2EzOjB2NEG2OC=>
HL60 cells MoHDR5l1d3SxeHnjbZR6KGG|c3H5 M{PoclczKGh? M1TxSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= M174RVIzOTN4M{Gy
HL60 cells MonuVJJwdGmoZYLheIlwdiCjc4PhfS=> MlLiO|IhcA>? MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? Mnr5NlI2PzhzMUG=
NCI-H522 cells NUfybWdsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFzZeXk1QCCq NXTubZl{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M3qwbVIzQTh{MUKy
MDA-MB-435 cells NIHWVYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV60PEBp Mmj2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MUGyNlk5OjF{Mh?=
OVCAR3 NEDaeJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIi5R4M1QCCq MVLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NFvrSVkzOjl6MkGyNi=>
NCI/ADR-RES cells MnnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zkSFQ5KGh? MmPhS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NFi2R4IzOjl6MkGyNi=>
PC3 cells M{P4OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzTT481QCCq NUfiZ2dqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NE[4XWgzOjl6MkGyNi=>
DU145 cells NELicohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2\EVlQ5KGh? NYCxNZQyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NXe0VWs3OjJ7OEKxNlI>
MDA-MB-231 cells MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4fUZlQ5KGh? M1\ke2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MoLENlI6QDJzMkK=
CEM cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= Mm\pO|IhcA>? NGX6[3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MkGxNlI3PzZ{NEe=
HCT116 cells MkTlR5l1d3SxeHnjbZR6KGG|c3H5 MYK3NkBp MmDnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MmLUNlI3PzZ{NEe=
MDA-MB-435 cells NVXDc4xFS3m2b4TvfIlkcXS7IHHzd4F6 NVq4OldWPzJiaB?= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M4GwTlIzPjd4MkS3
HaCaT cells NEP5UlBRem:uaX\ldoF1cW:wIHHzd4F6 MkDBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MmG2NlMxPjN2MEG=
HL60 cells NEHNdlNRem:uaX\ldoF1cW:wIHHzd4F6 MoXaO|IhcA>? NIP6eVFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MonTNlMyOTdzN{G=
HL60 cells M1y1W3Bzd2yrZnXyZZRqd25iYYPzZZk> MWi3NkBp MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KCh|LTi0MFUu\GmvZYTofYx1cGmjen;sMVIugWxrLUKsOU1lcXCqZX75cJRmfHKjen;sbZVuKGK{b33p[IUhfGW|dDygTWM2OD1yLkCwNUDPxE1? NH;1VW0zPTd6NU[wOS=>
HT-29 NIDO[JBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmf1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M1W5T|I2Pjh7MUGx
HL60 cells M{fEbXBzd2yrZnXyZZRqd25iYYPzZZk> MXy3NkBp M2nK[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? M3XuZVIxPDJyNEO5
Hs578T cells M330e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWnLVo9OPDhiaB?= MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MYiyNlk5OjF{Mh?=
HL60 cells M2jLS2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXW3NkBp NX;jeos4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MUmyN|Q1PTR7Nh?=
SKOV3 cells MnK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NXTi[G1NOjV4OEmxNVE>
MDA-MB-468 cells NVnodVQ6S3m2b4TvfIlkcXS7IHHzd4F6 NG\wN401KGSjeYO= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDRiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGxJO69VQ>? NEXHZmUzPDJzMEWwNy=>
MCF7 cells NYXhTmxEWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUPWdHVyPzJiaB?= MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEyOSEQvF2= MYqyNlMzQTV4MR?=
H460 NWr6cpRTS3m2b4TvfIlkcXS7IHHzd4F6 NEHleGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN MVWxPFc5OzJyNx?=
H460 NG\hUHlRem:uaX\ldoF1cW:wIHHzd4F6 NVyydVhUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzMEBKSzVyPUCuNFAyOjRizszN Mk\TNVY4OjJ4M{O=
NCI-H460 cells MlnkR5l1d3SxeHnjbZR6KGG|c3H5 Moj5O|IhcA>? MWTDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjD0[ZN1NCCLQ{WwQVAvODBzMzFOwG0> MoTFNVg{QTZ6NUe=
OVCAR8 cells NGXmc3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4j2fVk3KGh? NVXX[3E4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK4JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ3z5Z49xem:2ZXnuJIFnfGW{IEm2JIhzeyxiSVO1NF0xNjByMUOg{txO MX[yNlA1PDF4NB?=
NCI/ADR-RES cells M1XsbmN6fG:2b4jpZ4l1gSCjc4PhfS=> NFfMfWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= MkL2NlMzOTR2NUK=
OVCAR8 cells NY\Y[HBkS3m2b4TvfIlkcXS7IHHzd4F6 MYC5OkBp M{PmUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= MVuyOVAzPTl7MR?=
NCI/ADR-RES cells Mom3R5l1d3SxeHnjbZR6KGG|c3H5 NVvXe25wQTZiaB?= M{ntV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS:DRGKtVmVUKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFk3KGi{czDifUBIcWWvc3Ggd5RicW6rbnetZoF{\WRibHnnbJQhdWmlcn;zZ49xgSxiSVO1NF0xNjByMUOg{txO NVHiZ2pmOjVyMkW5PVE>
OVCAR8 cells NWDmeJZIS3m2b4TvfIlkcXS7IHHzd4F6 M2nG[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUB1enmyYX6gZox2\SCneHPseZNqd25iYYPzZZktKEmFNUC9NE4xODF|IN88US=> NFzxdmkzOzJzNES1Ni=>
HuTu 80 cells M4\RSHBzd2yrZnXyZZRqd25iYYPzZZk> NGr6[oQ4OiCq MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDIeXR2KDhyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF|NzFOwG0> NFzydXMzOjN{OUW2NS=>
K562 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= NIP1b3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{NCCLQ{WwQVAvODBzNDFOwG0> MV6xPVg{PzV7NB?=
NCI/ADR (MDR) cells MkDMSpVv[3Srb36gZZN{[Xl? NWHnW5k{S2WubDDjfYNt\SCjcoLld5QhcW5iTlPJM2FFWiBqTVTSLUBk\WyuczDifUBi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UwhUUN3ME2wMlAxOTVizszN MnTaNVY{PzdzOEe=
HUVEC MoPCVJJwdGmoZYLheIlwdiCjc4PhfS=> NFrTSGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> NHLuTJkyPjd{Mk[zNy=>
KB cell MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NGOzNHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGxibHnu[UBjgSCvZYTofYxmdmViYnz1[UBlgWViYYPzZZktKEmFNUC9NE4xODF3IN88US=> MoW0NVcxOzRzNEe=
KB-VIN10 cell NUO0PVc1WHKxbHnm[ZJifGmxbjDhd5NigQ>? M1zvTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscEBtcW6nIHL5JI1mfGi7bHXu[UBjdHWnIHT5[UBie3OjeTygTWM2OD1yLkCwNVUh|ryP MV[xO|A{PDF2Nx?=
Human SH-SY5Y neuroblastoma cells MkfNSpVv[3Srb36gZZN{[Xl? NWjNOYsxUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? NED5N5gyPTl4M{eyNi=>
SW620 cells M3;FS3Bzd2yrZnXyZZRqd25iYYPzZZk> MlvTO|IhcA>? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN MWSyNlMzQTV4MR?=
Molt4/C8 cells NF3Tem9Rem:uaX\ldoF1cW:wIHHzd4F6 M2rLfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> M4LWOlE4ODN2MUWw
ACHN cell MUXQdo9tcW[ncnH0bY9vKGG|c3H5 M4rCSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> Mnz2NVczQDZ|OUO=
Molt4/C8 cells NFvXeoZRem:uaX\ldoF1cW:wIHHzd4F6 NFHlZnU{KGSjeYO= NUGyd21rSW62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMh[W[2ZYKgN{Bl[Xm|LDDJR|UxRTBwMECxOkDPxE1? MWexO|QyQTZyNx?=

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(O)C=C(\C=C/C2=CC(=C(OC)C(=C2)OC)OC)C=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID